Last reviewed · How we verify
Transarterial Radioembolization Versus Chemoembolization for the Treatment of Advanced Hepatocellular Carcinoma
Hepatocellular Carcinoma (HCC) is a primary liver cancer. It is the 6th most common malignancy and the 3rd killers of all tumors worldwide with an incidence of 626,000 new patients a year. The intermediate stage of HCC is controlled by radiological interventions such as Transarterial Chemoembolization (TACE) or Radioembolization. Although 90Y radioembolization is increasingly being used in clinical practice, there is no high quality clinical evidence to justify this. To date, no prospective studies have been performed comparing both treatment modalities (TACE vs 90Y) in a randomized setting. This randomized controlled trial is designed to prospectively compare TACE and 90Y for treatment of patients with unresectable (BCLC intermediate stage) HCC. This will be done by recruiting 75 patients in each arm from. Investigators will compare between the two groups the time to progression (TTP) as the primary outcome and also examine time to local progression (TLP) as well as other factors like overall survival, response to therapy, toxicities and adverse events, quality of life and treatment-related costs.
Details
| Lead sponsor | King Faisal Specialist Hospital & Research Center |
|---|---|
| Phase | Phase 4 |
| Status | UNKNOWN |
| Enrolment | 150 |
| Start date | 2016-01 |
| Completion | 2017-12 |
Conditions
- Hepatocellular Carcinoma
Interventions
- Transarterial Radioembolization
- Transarterial Chemoembolization using drug-eluting beads
Primary outcomes
- Time to Progression (TTP) is the primary outcome. — 12 month
Countries
Saudi Arabia